A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults with Cutaneous Sarcoidosis (BEACON) (BEACON)

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

The purpose of this research is to measure clinical safety and efficacy of oral brepocitinib in adults 18 and over diagnosed with cutaneous sarcoidosis. Procedures include Medical history, Physical exam, EKG, PFT, Photography, Biopsy, blood and urine collection.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 17 Jun 2025. Study ID: 24-2277
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research